TL;DR — what is AOD-9604?
AOD-9604 is a 16-amino-acid fragment of human growth hormone (specifically the C-terminal region 176–191) engineered to retain the lipolytic (fat-burning) effects of HGH without affecting glucose, insulin, or cell proliferation. It is one of the most studied peptides for targeted fat metabolism.
How AOD-9604 works (the science, in plain language)
Full-length HGH does many things — some desirable, some not. Researchers asked: which part of HGH actually drives fat burning? The answer is a small tail at amino acids 176–191. AOD-9604 isolates that fragment and adds a tyrosine residue for stability. The mechanism: it stimulates lipolysis (fat breakdown) in adipose tissue and inhibits lipogenesis (fat storage) by activating beta-3 adrenergic receptors on fat cells. Crucially, it does NOT activate the IGF-1 axis, which means none of the blood-sugar disruption, joint changes, or organ-growth signals associated with full-length HGH. Half-life is short (~30 minutes), so clinical protocols typically use daily subcutaneous administration. The peptide also shows secondary cartilage-supportive effects in some studies, leading to performance and recovery applications.
What clinical research shows
A 12-week double-blind trial published in the Journal of Clinical Endocrinology & Metabolism (Ng et al., 2003) tested AOD-9604 in obese subjects, showing significantly greater body-weight reduction than placebo without the metabolic disruption seen with full HGH. Earlier mechanism-of-action work in Endocrinology (2000) demonstrated lipolytic activity in adipocytes without IGF-1 elevation — the foundation of the molecule's safety profile.
Reference dosing from clinical trials
Consult a licensed Philippine medical professional before starting any peptide protocol. Published protocols typically use 250–500mcg administered once daily via subcutaneous injection, often pre-breakfast on an empty stomach to maximize the lipolytic window. Some clinical-research stacks split dosing morning and pre-workout. Cycles commonly run 8–12 weeks with planned breaks.
Common side effects (and how individuals manage them)
- Injection-site irritation — rotate between abdomen and thigh.
- Mild fatigue — typically only in week 1.
- Headache — hydration helps; usually transient.
- Vivid dreams — occasional, related to mild HGH-axis adjacency.
- No insulin or glucose impact — a key advantage over full HGH.
How AOD-9604 compares to other peptides
Versus Tirzepatide or Retatrutide — AOD-9604 doesn't suppress appetite. It works on fat cells directly. Researchers use it for body-composition studies where preserving appetite (and food intake control) matters. Versus MOTS-c, AOD-9604 is more lipolysis-targeted while MOTS-c works on mitochondrial energy efficiency. The two are sometimes paired in performance clinical-research stacks. AOD-9604 is also commonly grouped with lipolytic injectables like Lemon Bottle for body-recomposition research.
Buying AOD-9604 in the Philippines
Noki Labs supplies lab-tested AOD-9604 2mg vials at ₱1,500, shipped cold-chain nationwide. Cash-on-delivery, 1–7 day delivery, free shipping over ₱2,500 with FREESHIP. Baguio and General Santos lead AOD-9604 demand among performance-research customers — see Peptide Supplier Baguio. Go to the AOD-9604 product page, browse Weight Management or Performance & Recovery. Shipping info: Shipping & Delivery.
FAQ
Does AOD-9604 affect blood sugar?
Trial data shows no significant impact on insulin sensitivity or glucose levels — the molecule's defining safety advantage over full HGH.
Daily injections — why not weekly?
Half-life is roughly 30 minutes; daily administration maintains steady research signal.
Can AOD-9604 build muscle?
It is a lipolytic, not anabolic. Body-composition changes show as fat reduction without muscle accrual.
How long is a typical reference cycle?
Published reference cycles range 8–12 weeks with planned off-cycle periods.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ